StreetInsider.com News Articles

Polaryx Therapeutics names Will Charlton as chief medical officer

Tue, 01 Sep 2026 08:30:25 -0400

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company focused on rare pediatric lysosomal storage disorders, announced the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026.

Dr. Charlton is a board-certified pediatric endocrinologist with approximately two decades of experience in rare disease and pediatric drug development. Before joining Polaryx, he served as Senior Vice President of Clinical Development for Skeletal Dysplasia at Tyra Biosciences, where he led a Phase 2 rare disease clinical trial program. Prior to that role, he served as Chief Medical Officer at Spruce Biosciences, where he led clinical development strategy for

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Tue, 01 Sep 2026 08:30:00 -0400

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles

Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation in Q4 2026

PARAMUS, NJ, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today announced the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. With nearly two decades of leadership experience as a Chief

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Tue, 01 Sep 2026 08:30:00 -0400

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles

Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation in Q4 2026

Polaryx targets Q4 2026 launch of SOTERIA Phase 2 trial

Tue, 25 Aug 2026 08:30:29 -0400

Polaryx Therapeutics (NASDAQ: PLYX) provided an update on preparations for SOTERIA, its Phase 2 basket trial evaluating drug candidate PLX-200 across four rare pediatric lysosomal storage disorders (LSDs): CLN2 disease, CLN3 disease, Krabbe disease, and Sandhoff disease.

The company said it plans to initiate the trial in the fourth quarter of 2026. According to a press release, key elements supporting trial initiation include FDA authorization to proceed, engagement of a contract research organization, FDA Fast Track Designation for PLX-200 across all four indications, and completion of a $10 million financing. The trial has been registered on ClinicalTrials.gov under identifier NCT07740512.

SOTERIA is

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Tue, 25 Aug 2026 08:30:00 -0400

Company on track to initiate SOTERIA trial in the second half of 2026

Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication

PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs.

Polaryx continues to advance clinical trial start-up activities in collaboration

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Tue, 25 Aug 2026 08:30:00 -0400

Company on track to initiate SOTERIA trial in the second half of 2026

Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication

Polaryx continues to advance clinical trial start-up activities in collaboration

Form 10-Q Polaryx Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260813/26921399.html

Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy

Thu, 13 Aug 2026 06:07:06 -0400

(Updated - August 13, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Strong Buy rating and a price target of $6.00.

The analyst comments "We are initiating coverage of Polaryx Therapeutics, Inc. (PLYX) at Strong Buy with a $6 target price. Polaryx is an early-stage biotechnology company developing therapies for rare pediatric lysosomal storage disorders (LSD). The company is advancing PLX-200, an oral solution formulation of a small molecule previously studied for lipid lowering. PLX-200 will be studied in the Phase 2 SOTERIA trial (on track for first site activation and patient

Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy

Thu, 13 Aug 2026 06:07:06 -0400

(Updated - August 13, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Strong Buy rating and a price target of $6.00.

Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy

Thu, 13 Aug 2026 06:07:06 -0400

(Updated - August 13, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Strong Buy rating and a price target of $6.00.

Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy

Thu, 13 Aug 2026 06:07:06 -0400

(Updated - August 13, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Strong Buy rating and a price target of $6.00.

Form ARS Polaryx Therapeutics, For: Dec 31

Tue, 28 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260728/26828256.html

Form DEFA14A Polaryx Therapeutics,

Tue, 28 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260728/26828221.html

Form DEF 14A Polaryx Therapeutics, For: Sep 10

Tue, 28 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260728/26828198.html

Lucid Capital Markets Starts Polaryx Therapeutics (PLYX) at Buy

Mon, 27 Jul 2026 06:32:49 -0400

Lucid Capital Markets analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $7.00.

The analyst comments "We initiate coverage of Polaryx Therapeutics (PLYX) with a Buy rating and $7 price target. PLYX is developing disease-modifying therapies for rare pediatric lysosomal storage diseases (LSDs), led by PLX-200, a proprietary oral-solution formulation of gemfibrozil designed to cross the blood-brain barrier and address lysosomal dysfunction, neuroinflammation, and neuronal loss. Our investment thesis centers on the Phase 2 SOTERIA basket trial, which offers a capital-efficient opportunity to establish human proof of concept across CLN2, CLN3,

Lucid Capital Markets Starts Polaryx Therapeutics (PLYX) at Buy

Mon, 27 Jul 2026 06:32:49 -0400

Lucid Capital Markets analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $7.00.

Form S-8 Polaryx Therapeutics,

Fri, 24 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260724/26813896.html

Form 8-K Polaryx Therapeutics, For: Jul 19

Tue, 21 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260721/26796059.html

Form 8-K Polaryx Therapeutics, For: Jul 16

Fri, 17 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260717/26782106.html

H.C. Wainwright Starts Polaryx Therapeutics (PLYX) at Buy

Thu, 09 Jul 2026 06:45:21 -0400

H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $7.00.

The analyst comments "PLX-200 targets fatal pediatric CNS-LSDs with a repurposed oral drug with impressive data, yet a ~$100M EV gives little credit. We are initiating coverage of Polaryx Therapeutics with a Buy rating and $7 PT, driven by what we view as an underappreciated orphan-disease setup: PLX-200 uses a long-approved active ingredient, targets shared downstream lysosomal dysfunction across severe pediatric CNS-LSDs, and enters SOTERIA with preclinical evidence of target engagement, cellular waste reduction, motor benefit, and survival extension

H.C. Wainwright Starts Polaryx Therapeutics (PLYX) at Buy

Thu, 09 Jul 2026 06:45:21 -0400

H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $7.00.

Form 4 Polaryx Therapeutics, For: May 27 Filed by: Yang Alex Keun Mo

Thu, 28 May 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260528/26569357.html

Form 8-K Polaryx Therapeutics, For: May 27

Thu, 28 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260528/26567994.html

Polaryx Therapeutics raises $10 million to fund phase 2 trial

Thu, 28 May 2026 08:30:35 -0400

Polaryx Therapeutics Inc. (NASDAQ: PLYX) closed a $10 million private investment in public equity financing on May 28, 2026, the clinical-stage biotechnology company announced.

The financing consisted of 2,502,696 shares of common stock sold at an average price of approximately $4.00 per share. Polaryx develops therapies for rare pediatric lysosomal storage disorders.

The company plans to use the proceeds along with existing cash to fund the initiation of its Phase 2 SOTERIA trial, which will evaluate PLX-200 across multiple lysosomal storage disorder indications. The funds will also support continued research and development of product candidates and general corporate purposes.

"This financing provides us

Polaryx Therapeutics raises $10 million to fund phase 2 trial

Thu, 28 May 2026 08:30:35 -0400

Polaryx Therapeutics Inc. (NASDAQ: PLYX) closed a $10 million private investment in public equity financing on May 28, 2026, the clinical-stage biotechnology company announced.

The financing consisted of 2,502,696 shares of common stock sold at an average price of approximately $4.00 per share. Polaryx develops therapies for rare pediatric lysosomal storage disorders.

"This financing provides us